Memantine, NMDA Receptor Antagonist, Attenuates ox-LDL-Induced Inflammation and Oxidative Stress via Activation of BDNF/TrkB Signaling Pathway in HUVECs

Inflammation. 2021 Apr;44(2):659-670. doi: 10.1007/s10753-020-01365-z. Epub 2020 Nov 10.

Abstract

Atherosclerosis is a chronic cardiovascular disease and contributes to pathogenesis of most myocardial infarction and ischemic stroke. Additionally, N-methyl-D-aspartate (NMDA) receptor plays a crucial role in myocardial infarction and ischemic strokes. The aim of our study was to investigate the underlying mechanisms of memantine (MEM), the blocker of NMDA receptors, in the development of atherosclerosis. In our study, human umbilical vascular endothelial cells (HUVECs) were stimulated with low-density lipoprotein (ox-LDL) to establish an atherosclerotic cell model. Cell Counting Kit-8 (CCK-8) assay and TUNEL staining were performed to detect the cell activity and apoptosis of HUVECs, respectively. The levels of inflammatory cytokines and malondialdehyde and the activities of lactate dehydrogenase (LDH), superoxide dismutase (SOD), and caspase-1 were quantified with commercial assay kits. Finally, qRT-PCR assay and western blot analysis were carried out to determine the mRNA and protein expressions of inflammation-related genes in HUVECs. The results of the present study suggested that ox-LDL stimulation induced decreased viability of HUVECs, excessive inflammation, and oxidative stress, while these effects were counteracted by MEM treatment. Interestingly, MEM triggered the activation of BDNF/TrkB signaling pathway in HUVECs, and K252a, the inhibitor of the BDNF/TrkB pathway, abolished the suppressive effect of MEM on ox-LDL-induced inflammation, oxidative stress, and apoptosis in HUVECs. Overall, MEM attenuated ox-LDL-induced inflammation, oxidative stress, and apoptosis via activation of BDNF/TrkB signaling pathway in HUVECs, indicating that MEM may be defined as a novel and effective agent for atherosclerosis treatment.

Keywords: N-methyl-D-aspartate (NMDA) receptor; atherosclerosis; inflammation; memantine; oxidative stress.

MeSH terms

  • Apoptosis / drug effects
  • Atherosclerosis / drug therapy*
  • Atherosclerosis / etiology
  • Atherosclerosis / metabolism
  • Biomarkers / metabolism
  • Blotting, Western
  • Brain-Derived Neurotrophic Factor / metabolism*
  • Cells, Cultured
  • Cytokines / metabolism
  • Enzyme-Linked Immunosorbent Assay
  • Excitatory Amino Acid Antagonists / pharmacology*
  • Excitatory Amino Acid Antagonists / therapeutic use
  • Human Umbilical Vein Endothelial Cells / drug effects
  • Human Umbilical Vein Endothelial Cells / metabolism
  • Humans
  • In Situ Nick-End Labeling
  • Inflammation / drug therapy*
  • Inflammation / etiology
  • Inflammation / metabolism
  • Lipoproteins, LDL
  • Memantine / pharmacology*
  • Memantine / therapeutic use
  • Membrane Glycoproteins / metabolism*
  • Oxidative Stress / drug effects*
  • Receptor, trkB / metabolism*
  • Receptors, N-Methyl-D-Aspartate / antagonists & inhibitors
  • Reverse Transcriptase Polymerase Chain Reaction
  • Signal Transduction / drug effects

Substances

  • Biomarkers
  • Brain-Derived Neurotrophic Factor
  • Cytokines
  • Excitatory Amino Acid Antagonists
  • Lipoproteins, LDL
  • Membrane Glycoproteins
  • Receptors, N-Methyl-D-Aspartate
  • oxidized low density lipoprotein
  • BDNF protein, human
  • Receptor, trkB
  • tropomyosin-related kinase-B, human
  • Memantine